The interest in finding new formulas for biotechnological research, as well as discovering new products to solve some of the most significant therapeutic vacuums moved a select group of experts to come together in the 90s. In informal meetings they discussed and reviewed some of the most important medical controversies concerning the approach to treating certain Ear, Nose and Throat (ENT) illnesses.

Dr. Margaret Mtchedlidze participated in the founding scientific committee, and became the Alma Mater of this group of experts. An Academic, doctor in Biology, Deacon of the Faculty for Subtropical Plants and holder of the Chair for Plant Ecology at the State Institute for Subtropical Cultures, was moved by her interest to find a solution for rhinosinusitis, and so contacted some of the most prestigious authorities on ENT disease.

At these meetings, in Margaret Mtchedlidze‘s house, experts of prestigious international renown participated:

  • Professor Michael Gedevanishvili. Scientific Director Research and Development Institute in Pharmaceutical Chemistry.
  • Professor Gunter Mlynski. Medical Vice Director of ENT at the Ernst Moritz Arndt University in Greifswald (Germany).
  • Professor Simon Khechinashvili. Academician, Head of ENT at the Tbilisi State Medical. Academy. Honorary Doctor of the Humboldt University (Berlin, Germany), member of the German Academy of Natural Sciences (Leopoldina), Lenin Prize 1964.
  • Professor Shota Japaridze. Director of the ENT Clinic at the State Medical University of Tbilisi.
How it all started Hartington

In this discussion, together with the initial committee, the following experts also participated:

  • Professor Vasil Popovich. Holder of the ENT Chair at the Ivano-Frankivsk state medical university, Ukraine.
  • Professor Florian Hoppe. Medical Director of the ENT Clinic at Municipal Clinics Oldenburg (Germany).
  • Professor Dimitry Zabolotny. Director of the ENT Institute Ukraine Science Academy.
  • Dr. Klaus Zimmermann. Pharmaceutical Chemist (Germany).

The main point of discussion among these experts was the lack of medicines capable of tackling a growing problem. Everyone coincided in expressing their concern regarding the therapeutic vacuum that existed in treating ENT diseases that were especially prevalent, such as acute and chronic rhinosinusitis, insisting above all on one unquestionable fact:

In spite of the treatment received, some 15% of acute rhinosinusitis cases actually worsened” and even after 4 weeks of treatment remain unsolved, according to recent epidemiological studies: PROSINUS 2008.


Once the situation had been reviewed, Dr. Vakhtang Mtchedlidze headed a group of experts, both leading and coordinating an exchange of ideas concerning the search for the ideal product to treat rhinosinusitis.

To this day the project is supported by an Independent Scientific Advisory Committee formed by leading specialists from the ENT field.